Related Experiment Video
Updated: Aug 12, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
[Progress and controversy in treatment of Hodgkin's disease]
1Kliniki Hematologii AM w Lodzi.
Hodgkin's disease (HD) is a malignant disease originating from hematopoietic tissue which is characterized by the presence of Hodgkin and Reed-Sternberg cells. The vast majority of HD patients are cured with current standard therapy. Both megavoltage radiotherapy and combination chemotherapy are effective treatment modalities. Radiotherapy is curative for localized Hodgkin's disease, and it is now generally agreed that advanced Hodgkin's disease can be cured by combination chemotherapy. Data from uncontrolled trials suggest that in patients with advanced disease the addition of low-dose radiation to sites of previous disease involvement is associated with better long term and relapse free survival. Patients who relapse after initial treatment with chemotherapy are considered suitable candidates for systemic salvage programs. These programs may include treatment with the same drugs, the use of non-cross resistant chemotherapy programs or investigational programs such as high dose chemotherapy with autologous or allogenic bone marrow rescue. An appropriate management decision depends upon assessment of the disease and also on the impact of treatment side effects on the individual patients.
Hodgkin's disease (HD) is a malignant disease originating from hematopoietic tissue which is characterized by the presence of Hodgkin and Reed-Sternberg cells. The vast majority of HD patients are cured with current standard therapy. Both megavoltage radiotherapy and combination chemotherapy are effective treatment modalities. Radiotherapy is curative for localized Hodgkin's disease, and it is now generally agreed that advanced Hodgkin's disease can be cured by combination chemotherapy. Data from uncontrolled trials suggest that in patients with advanced disease the addition of low-dose radiation to sites of previous disease involvement is associated with better long term and relapse free survival. Patients who relapse after initial treatment with chemotherapy are considered suitable candidates for systemic salvage programs. These programs may include treatment with the same drugs, the use of non-cross resistant chemotherapy programs or investigational programs such as high dose chemotherapy with autologous or allogenic bone marrow rescue. An appropriate management decision depends upon assessment of the disease and also on the impact of treatment side effects on the individual patients.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tumor Immunotherapy